Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with ICE (etoposide, carboplatin, and ifosfamide) for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin's lymphoma (HL).

This is written in the approval document as:

Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)

Citation

Brentuximab vedotin and ICE Therapy, 2020, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/528.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	CD30 +, HER2-negative	Hodgkin Lymphoma	Brentuximab Vedotin, Carboplatin, Etoposide, Ifosfamide